Wen-Kuan Huang

Dr. Wen-Kuan Huang

Karolinska Institutet
+1
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in Medicine
Verified
Journal Article
Open access
KYKuang-Hui Yu
Kuang-Hui Yu
CKChang-Fu Kuo
Chang-Fu Kuo
LHLu Hsiang Huang
Lu Hsiang Huang
WHWen-Kuan Huang
Wen-Kuan Huang
LSLai-Chu See
Lai-Chu See
The aim of this study was to determine whether inflammation is related to cancer development, and whether the incidence of cancer is increased and occurs in a site-specific manner in patients with systemic autoimmune rheumatic diseases (SARDs). This study included a nationwide dynamic cohort of patients with various newly diagnosed SARDs from 1997 to 2010 with follow-up until 2012. This study included 75,123 patients with SARDs. During 562,870 person-years of follow-up, 2844 patients developed cancer. Between 1997 and 2010, the highest number of newly diagnosed SARDs cases were rheumatoid arthritis (n = 35,182), followed by systemic lupus erythematosus (SLE, n = 15,623), Sjögren syndrome (n = 11,998), Kawasaki disease (n = 3469), inflammatory bowel disease (n = 2853), scleroderma (n = 1814), Behçet disease (n = 1620), dermatomyositis (n = 1119), polymyositis (n = 811), and vasculitis other than Kawasaki disease (n = 644). A significant standardized incidence ratio (SIR) of overall cancer was observed for patients with SLE (1.41; 95% confidence interval [CI], 1.28–1.56), Sjögren syndrome (1.19; 95% CI, 1.08–1.30), scleroderma (1.27; 95% CI, 1.02–1.59), dermatomyositis (4.79; 95% CI, 4.01–5.73), polymyositis (1.47; 95% CI, 1.05–2.06), vasculitis excluding Kawasaki disease (1.75; 95% CI, 1.20–2.55), and Kawasaki disease (2.88; 95% CI, 1.60–5.20). Overall, patients with most SARDs had a significantly higher risk of inflammation-associated site-specific cancers and hematologic malignancies. This study confirms that autoimmunity is associated with site-specific and hematological malignancies and provides clinical evidence of an association between inflammation and subsequent site-specific cancer development. These findings support the importance of inflammation in site-specific organ system carcinogenesis.

1 October 2020 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
DCDong-Yi Chen
Dong-Yi Chen
WHWen-Kuan Huang
Wen-Kuan Huang
VWVictor Chien-Chia Wu
Victor Chien-Chia Wu
WCWen-Cheng Chang
Wen-Cheng Chang
JCJen-Shi Chen
Jen-Shi Chen
Pao-Hsien ChuPao-Hsien Chu
Pao-Hsien Chu
Immune checkpoint inhibitors (ICIs) are a novel treatment option for cancer therapy, which help direct the immune system to recognize and target cancer cells. ICIs have been shown to provide significant mortality benefits for cancer patients, but they are also associated with immune-mediated toxicity. Unlike most immune-related adverse events, which are a common occurrence, reversible and can be treated effectively with glucocorticoid therapy, ICI-associated cardiotoxicities are uncommon, with serious complications and a relatively high mortality even when treated with glucocorticoids. ICI-associated cardiotoxicity can manifest in various ways, including myocarditis, arrhythmias and conduction disease, pericardial disease, myocardial infarction, non-inflammatory cardiomyocyte dysfunction, and even Takotsubo-like cardiomyopathy. The present review summarizes the current understanding of ICI-associated cardiotoxicities, examining the epidemiology and timing of onset, as well as their clinical presentation, diagnostic modalities, pathophysiology, clinical management and outcomes. Although the literature describing ICI-associated cardiotoxicity remains limited to case reports, case series and early clinical trials, strategies for the surveillance, diagnosis and management of this potentially fatal cardiovascular complication of cancer therapy have been proposed.

15 November 2012 in Colorectal Disease
Verified
Journal Article
Closed access
PDF file
WHWen-Kuan Huang
Wen-Kuan Huang
JCJ. W.‐C. Chang
J. W.‐C. Chang
LSLai-Chu See
Lai-Chu See
HTH.‐T. Tu
H.‐T. Tu
JCJ.‐S. Chen
J.‐S. Chen
TYT.‐S. Yang
T.‐S. Yang

10 November 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
DCDong-Yi Chen
Dong-Yi Chen
LSLai-Chu See
Lai-Chu See
JLJia-Rou Liu
Jia-Rou Liu
CCCheng-Keng Chuang
Cheng-Keng Chuang
SPSee-Tong Pang
See-Tong Pang
WHWen-Kuan Huang
Wen-Kuan Huang
Purpose: Our aim was to determine whether cardiovascular (CV) risk in patients with prostate cancer (PCa) differs between those who receive androgen-deprivation therapy by surgical castration and those who receive gonadotropin-releasing hormone agonist (GnRHa) therapy.Patients and Methods: By using the Taiwan National Health Insurance Research Database, we analyzed data from 14,715 patients with PCa diagnosed from January 1, 1997, through December 31, 2011. The patients were treated with bilateral orchiectomy or GnRHa therapy. We used inverse probability of treatment weighting with propensity scores to adjust for the imbalance in covariate baseline values between these two groups. Cox regression models were used to identify risk factors for myocardial infarction (MI), ischemic stroke (IS), and cardiac-related complications.Results: Overall, 3,578 patients with PCa (24.3%) underwent bilateral orchiectomy and 11,137 patients (75.7%) received GnRHa therapy. Both groups had a similar risk of CV ischemic events (ie, MI or IS; hazard ratio, 1.16; 95% CI, 0.97 to 1.38) during a median follow-up time of 3.3 years. However, during the first 1.5 years of follow-up, there were higher CV ischemic events in the orchiectomy group than in the GnRHa group (hazard ratio, 1.40; 95% CI, 1.04 to 1.88), particularly in patients who were ≥ 65 years of age, had hypertension, had a Charlson comorbidity index score ≥ 3, and had a previous history of MI, IS, or coronary heart disease.Conclusion: Compared with bilateral orchiectomy, use of GnRHa does not increase the risk of CV ischemic events in patients with PCa. Nonetheless, orchiectomy is associated with higher rates of CV ischemic events in older patients and those with a history of CV comorbidities within 1.5 years of initiating androgen-deprivation therapy. These findings can help clinicians decide on the optimal castration strategy for individual patients.

17 August 2016 in Scientific Reports
Verified
Journal Article
Open access
PSPo-Jung Su
Po-Jung Su
MWMin-Hsien Wu
Min-Hsien Wu
HWHung-Ming Wang
Hung-Ming Wang
CLChia-Lin Lee
Chia-Lin Lee
WHWen-Kuan Huang
Wen-Kuan Huang
JHJason Chia-Hsun Hsieh
Jason Chia-Hsun Hsieh
The role of circulating tumour cells (CTCs) in advanced oesophageal cancer (EC) patients undergoing concurrent chemoradiotherapy (CCRT) remains uncertain. A negative selection protocol plus flow cytometry was validated to efficiently identify CTCs. The CTC number was calculated and analysed for survival impact. The protocol’s efficacy in CTC identification was validated with a recovery rate of 44.6 ± 9.1% and a coefficient of variation of 20.4%. Fifty-seven patients and 20 healthy donors were enrolled. Initial staging, first response to CRT, and surgery after CRT were prognostic for overall survival, with P values of <0.0001, <0.0001, and <0.0001, respectively. The CTC number of EC patients is significantly higher (P = 0.04) than that of healthy donors. Multivariate analysis for disease-specific progression-free survival showed that surgery after response to CCRT, initial stage, and CTC number (≥21.0 cells/mL) played independent prognostic roles. For overall survival, surgery after CCRT, performance status, initial stage, and CTC number were significant independent prognostic factors. In conclusion, a negative selection plus flow cytometry protocol efficiently detected CTCs. The CTC number before CCRT was an independent prognostic factor in patients with unresectable oesophageal squamous cell carcinoma. Further large-scale prospective studies for validation are warranted.

27 March 2014 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
WHWen-Kuan Huang
Wen-Kuan Huang
MCMeng-Jiun Chiou
Meng-Jiun Chiou
CKChang-Fu Kuo
Chang-Fu Kuo
YLYung-Chang Lin
Yung-Chang Lin
KYKuang-Hui Yu
Kuang-Hui Yu
LSLai-Chu See
Lai-Chu See